SCHEMBL671480

SCHEMBL671480

CCCCCCCCNC(=O)c1coc(C2CCCN2)n1

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TBXA2R P21731 9/20 0.48
PRCP P42785 3/20 0.47
PTGER1 P34995 1/20 0.42
PTGER4 P35408 1/20 0.42
PTGFR P43088 1/20 0.42
PTGER3 P43115 1/20 0.42
PTGER2 P43116 1/20 0.42
PTGIR P43119 1/20 0.42
PTGDR Q13258 1/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NAAA Q02083 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL671481 1.00 TBXA2R (0.48) TBXA2RPRCPPTGER1PTGER4PTGFR
SCHEMBL2079988 0.75 CREBBP (0.36) ALDH1A1SMN1; SMN2
SCHEMBL13955408 0.74 TBXA2R (0.62) TBXA2R
SCHEMBL3436850 0.69 TBXA2R (0.47) TBXA2RALDH1A1LMNASMN1; SMN2
SCHEMBL475667 0.68 CHRM2 (0.44)
SCHEMBL475670 0.68 CHRM2 (0.44)
SCHEMBL30486916 0.68 TBXA2R (0.77) TBXA2R
SCHEMBL163520 0.68 HTT (0.46) KDM4EALDH1A1LMNASMN1; SMN2NAAA
SCHEMBL18286347 0.66 KDM4E (0.44) TBXA2RKDM4EALDH1A1LMNASMN1; SMN2
SCHEMBL11842693 0.65 PRCP (1.00) PRCPNAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9422273-B2 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2016-08-23 US disclosed
US-9422273-B2 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2016-08-23 US disclosed
US-9422273-B2 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2016-08-23 US disclosed
US-20160068520-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. 2016-03-10 US disclosed
US-20160068520-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. 2016-03-10 US disclosed
US-20160068520-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. 2016-03-10 US disclosed
US-9085567-B2 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2015-07-21 US disclosed
US-9085567-B2 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2015-07-21 US disclosed
US-9085567-B2 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2015-07-21 US disclosed
US-20140249192-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2014-09-04 US disclosed
US-20130150417-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-06-13 US disclosed
WO-2012145737-A1 FATTY ACID AMIDE HYDROLASE INHIBITORS FOR TREATING ALLERGAN, INC. (US) 2012-10-26 WO disclosed
US-20120270915-A1 FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN ENERGY, UNITED STATES DEPARTMENT OF 2012-10-25 US disclosed
US-20120270915-A1 FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN ENERGY, UNITED STATES DEPARTMENT OF 2012-10-25 US disclosed
US-20120270915-A1 FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN ENERGY, UNITED STATES DEPARTMENT OF 2012-10-25 US disclosed
US-20120077858-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2012-03-29 US disclosed
US-20120077858-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2012-03-29 US disclosed
US-20120077858-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2012-03-29 US disclosed
WO-2012024559-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2012-02-23 WO disclosed
WO-2012024559-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2012-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077858-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER3 TBXA2R 17/4885PRCP 2972/4885PTGER1 1/4885
US-20120270915-A1 FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN FAAH, FAAH2, FAH TBXA2R 143/4885PRCP 3383/4885PTGER1 26/4885
US-20130150417-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER3 TBXA2R 12/4885PRCP 1704/4885PTGER1 1/4885
US-20160068520-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER3 TBXA2R 17/4885PRCP 2972/4885PTGER1 1/4885
US-20140249192-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER3 TBXA2R 17/4885PRCP 2972/4885PTGER1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.